디지털 PCR 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of digital PCR Market

The global digital PCR market was valued at USD 857.2 million in 2025 and is projected to grow from USD 1,043.20 million in 2026 to USD 5,776.73 million by 2034, registering a CAGR of 23.90% during the forecast period. North America dominated the global market with a 43.70% market share in 2025, driven by early adoption of advanced molecular diagnostics, strong research funding, and widespread use of precision medicine technologies.

Digital polymerase chain reaction (dPCR) is an advanced molecular diagnostic technology that enables highly accurate and absolute quantification of DNA and RNA molecules. Compared to conventional PCR and real-time PCR, digital PCR offers superior sensitivity, precision, reproducibility, and the ability to detect rare genetic mutations. The growing prevalence of infectious diseases, cancer, and genetic disorders, coupled with increasing investments in molecular diagnostics and continuous technological innovations, is driving market expansion worldwide. The increasing adoption of digital PCR across clinical laboratories, pharmaceutical companies, biotechnology firms, and research organizations is further accelerating industry growth through 2034.

Market Drivers

Rising Prevalence of Infectious Diseases and Cancer Driving Product Demand

The increasing incidence of infectious diseases, oncology cases, and inherited genetic disorders has significantly increased the demand for highly sensitive molecular diagnostic technologies. Digital PCR enables precise detection of low-abundance nucleic acids, making it highly suitable for early disease diagnosis, liquid biopsy, mutation analysis, and infectious disease detection.

Healthcare providers are increasingly adopting digital PCR due to its ability to deliver absolute quantification without requiring standard curves while providing greater accuracy than conventional PCR methods. The technology has become an essential tool for precision medicine, personalized treatment planning, and advanced clinical research.

Continuous Technological Advancements Supporting Market Growth

Leading manufacturers continue introducing next-generation digital PCR platforms with improved automation, multiplexing capabilities, faster workflows, and enhanced sensitivity.

For example, in November 2022, Shenzhen New Industries Biomedical Engineering launched the Molecision S6 Digital PCR System, offering a fully automated integrated platform for research and in-vitro diagnostics. Similarly, Bio-Rad, Thermo Fisher Scientific, QIAGEN, and Roche continue expanding their product portfolios through innovative instrument launches and reagent development.

These technological improvements are expanding digital PCR applications across oncology, infectious disease testing, prenatal screening, transplant monitoring, and genetic research.

Market Restraints

Despite its advantages, digital PCR systems remain expensive compared to conventional PCR technologies. High equipment costs, costly consumables, and the requirement for trained laboratory personnel continue limiting adoption, particularly in developing countries.

In addition, the growing availability of alternative technologies such as next-generation sequencing (NGS) for genomic analysis creates competitive pressure. Limited accessibility to advanced laboratory infrastructure and microfluidic technologies further restrains market penetration in low-income regions.

Market Opportunities

Growing investments in precision medicine, companion diagnostics, and personalized healthcare are creating substantial opportunities for digital PCR manufacturers. Increasing collaborations between biotechnology companies, diagnostic manufacturers, and research institutions are accelerating product commercialization.

Emerging markets across Asia Pacific and Latin America are witnessing significant healthcare infrastructure improvements, creating new revenue opportunities. Government support for molecular diagnostic capabilities and increasing demand for advanced infectious disease testing are expected to further strengthen long-term market growth.

Market Trends

Shift Toward Chip-Based Digital PCR Technology

One of the major trends shaping the market is the gradual shift from droplet-based digital PCR systems to chip-based platforms. Chip-based systems reduce manual sample handling, minimize contamination risks, improve reproducibility, and simplify laboratory workflows.

Healthcare providers increasingly prefer chip-based technologies due to their faster processing, improved accuracy, lower operational complexity, and cost efficiency. This transition is expected to drive product innovation and increase adoption across both research and clinical settings.

Market Segmentation

By type, droplet digital PCR (ddPCR) is expected to remain the dominant segment in 2026, accounting for 82.04% of the global market due to its superior sensitivity and increasing use in infectious disease diagnostics. Chip-based digital PCR is projected to witness steady growth as laboratories increasingly adopt automated molecular testing platforms.

Based on product, instruments are expected to account for 59.01% of the market in 2026, supported by continuous product launches and increasing laboratory installations. Meanwhile, reagents and consumables are anticipated to record the fastest growth as testing volumes continue rising globally.

By indication, genetic disorders are projected to contribute 51.56% of global revenue in 2026, while oncology and infectious disease applications are expected to experience strong expansion driven by precision medicine and molecular diagnostics.

Based on end user, academic and research organizations are projected to dominate the market with 67.90% share in 2026, reflecting growing research activities involving cancer genomics, infectious diseases, and molecular biology. Clinical laboratories are expected to witness the fastest growth during the forecast period.

Regional Outlook

North America generated USD 374.68 million in 2025 and is expected to reach USD 456.47 million in 2026, maintaining its leadership due to strong research infrastructure, advanced laboratory adoption, and the presence of major industry participants.

Europe recorded USD 234.75 million in 2025 and is projected to reach USD 283.45 million in 2026. Increasing government investments in molecular diagnostics, expanding research funding, and favorable healthcare policies continue supporting regional market growth.

Asia Pacific reached USD 187.56 million in 2025 and is forecast to grow to USD 231.64 million in 2026. Rising healthcare investments, expanding diagnostic capabilities, growing infectious disease burden, and improving laboratory infrastructure are fueling rapid market expansion across China, Japan, India, and other emerging economies.

Latin America generated USD 32.37 million in 2025, while the Middle East & Africa accounted for USD 27.81 million. Growing healthcare modernization initiatives and increasing commercialization of advanced molecular diagnostic technologies are expected to gradually improve market penetration across these regions.

Competitive Landscape

The global digital PCR market remains highly consolidated, with major players focusing on technological innovation, acquisitions, product launches, and strategic collaborations to strengthen their competitive position.

Leading companies include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., QIAGEN, JN Medsys, Stilla, Sysmex Corporation, Standard BioTools Inc., and Precigenome LLC.

Recent industry developments include QIAGEN expanding its digital PCR kit portfolio, Thermo Fisher introducing advanced digital PCR research solutions, Bio-Rad strengthening its molecular diagnostics capabilities through acquisitions, and Stilla expanding global distribution partnerships to increase market reach.

Conclusion

The digital PCR market is expected to witness exceptional growth between 2026 and 2034, driven by increasing demand for precision diagnostics, continuous technological innovation, expanding applications in oncology and infectious diseases, and rising investments in molecular biology research. Strong adoption across clinical laboratories, pharmaceutical companies, and research institutions, combined with growing healthcare infrastructure in emerging economies, will continue supporting long-term global market expansion.

Growth Rate CAGR of 23.90% from 2026-2034

Segmentation

By Type

• Droplet Digital PCR
• Chip-based Digital PCR
• Others

By Product

• Instruments
• Reagents & Consumables

By Indication

• Infectious Diseases
• Oncology
• Genetic Disorders
• Others

By End-user

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Industries
• Clinical Laboratories
• Academic & Research Organizations

By Geography

• North America (By Type, Product, By Indication, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Product, By Indication, End-user, and Country/ Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Product, By Indication, End-user, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Product, By Indication, End-user, and Country/ Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Product, By Indication, End-user, and Country/ Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Chronic Diseases (Cancer and Infectious Disease), By Key Countries/Regions, 2025
• 4.2. Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
• 4.3. Regulatory Scenario, By Key Countries/Region
• 4.4. Technological Advancements in Digital PCR
• 4.5. Impact of Covid-19 on the Market

5. Global Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Droplet Digital PCR
  • 5.1.2. Chip-based Digital PCR
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Instruments
  • 5.2.2. Reagents & Consumables
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Infectious Diseases
  • 5.3.2. Oncology
  • 5.3.3. Genetic Disorders
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End-user
  • 5.4.1. Hospitals & Clinics
  • 5.4.2. Pharmaceutical & Biotechnology Industries
  • 5.4.3. Clinical Laboratories
  • 5.4.4. Academic & Research Organisations
• 5.5. Market Analysis, Insights and Forecast - By Geography
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Droplet Digital PCR
  • 6.1.2. Chip-based Digital PCR
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Instruments
  • 6.2.2. Reagents & Consumables
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Infectious Diseases
  • 6.3.2. Oncology
  • 6.3.3. Genetic Disorders
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By End-user
  • 6.4.1. Hospitals & Clinics
  • 6.4.2. Pharmaceutical & Biotechnology Industries
  • 6.4.3. Clinical Laboratories
  • 6.4.4. Academic & Research Organisations
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Droplet Digital PCR
  • 7.1.2. Chip-based Digital PCR
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Instruments
  • 7.2.2. Reagents & Consumables
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Infectious Diseases
  • 7.3.2. Oncology
  • 7.3.3. Genetic Disorders
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By End-user
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Pharmaceutical & Biotechnology Industries
  • 7.4.3. Clinical Laboratories
  • 7.4.4. Academic & Research Organisations
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Droplet Digital PCR
  • 8.1.2. Chip-based Digital PCR
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Instruments
  • 8.2.2. Reagents & Consumables
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Infectious Diseases
  • 8.3.2. Oncology
  • 8.3.3. Genetic Disorders
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By End-user
  • 8.4.1. Hospitals & Clinics
  • 8.4.2. Pharmaceutical & Biotechnology Industries
  • 8.4.3. Clinical Laboratories
  • 8.4.4. Academic & Research Organisations
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of APAC

9. Latin America Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Droplet Digital PCR
  • 9.1.2. Chip-based Digital PCR
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Instruments
  • 9.2.2. Reagents & Consumables
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Infectious Diseases
  • 9.3.2. Oncology
  • 9.3.3. Genetic Disorders
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By End-user
  • 9.4.1. Hospitals & Clinics
  • 9.4.2. Pharmaceutical & Biotechnology Industries
  • 9.4.3. Clinical Laboratories
  • 9.4.4. Academic & Research Organisations
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Digital PCR Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Droplet Digital PCR
  • 10.1.2. Chip-based Digital PCR
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. Instruments
  • 10.2.2. Reagents & Consumables
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Infectious Diseases
  • 10.3.2. Oncology
  • 10.3.3. Genetic Disorders
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By End-user
  • 10.4.1. Hospitals & Clinics
  • 10.4.2. Pharmaceutical & Biotechnology Industries
  • 10.4.3. Clinical Laboratories
  • 10.4.4. Academic & Research Organisations
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. QIAGEN
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (based on availability)
  • 11.2.2. Thermo Fisher Scientific Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (based on availability)
  • 11.2.3. Bio-Rad Laboratories, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (based on availability)
  • 11.2.4. JN Medsys
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (based on availability)
  • 11.2.5. Stilla
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (based on availability)
  • 11.2.6. Sysmex Corporation
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (based on availability)
  • 11.2.7. Standard BioTools Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (based on availability)
  • 11.2.8. Precigenome LLC.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (based on availability)